PA
PRVB

Perceptive Advisors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Perceptive Advisors’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-110,728
Closed -$498K – 120
2022
Q3 		$498K Hold
110,728
– – 0.01% 108
2022
Q2 		$443K Sell
110,728
-680,821
-86% -$3.23M 0.01% 106
2022
Q1 		$5.79M Sell
791,549
-156,932
-17% -$938K 0.12% 98
2021
Q4 		$5.33M Hold
948,481
– – 0.08% 115
2021
Q3 		$6.07M Hold
948,481
– – 0.09% 115
2021
Q2 		$8M Sell
948,481
-1,903,577
-67% -$15.4M 0.1% 114
2021
Q1 		$29.9M Sell
2,852,058
-1,372,331
-32% -$19.3M 0.38% 57
2020
Q4 		$71.6M Sell
4,224,389
-41,322
-1% -$619K 0.77% 36
2020
Q3 		$54.7M Sell
4,265,711
-260,000
-6% -$3.28M 0.8% 35
2020
Q2 		$63.9M Buy
4,525,711
+1,514,137
+50% +$19.1M 1.03% 25
2020
Q1 		$27.7M Buy
3,011,574
+90,000
+3% +$1.16M 0.72% 36
2019
Q4 		$43.5M Buy
2,921,574
+2,255,252
+338% +$20.1M 0.86% 27
2019
Q3 		$4.55M Buy
+666,322
New +$6.74M 0.12% 71

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Perceptive Advisors's PRVB Position: Q4 2022 in Review

Perceptive Advisors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q4 2022, closing a stake of 110,728 shares — an estimated $498K sold.

Perceptive Advisors first reported a position in PRVB in Q3 2019 and held it in 13 quarters. The position peaked at $71.6M in Q4 2020. 133 funds tracked by Wall St. Rank hold PRVB as of Q4 2022.

  • Perceptive Advisors reported no remaining Provention Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Perceptive Advisors sold 110,728 Provention Bio, Inc. Common Stock shares in Q4 2022, an estimated $498K.
  • Perceptive Advisors first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and held it in 13 quarters.
  • Perceptive Advisors's Provention Bio, Inc. Common Stock position peaked at $71.6M in Q4 2020.
  • 133 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q4 2022.

Based on Perceptive Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.